Download PDF
Exp Clin Endocrinol Diabetes 2018; 126(03): 187-193
DOI: 10.1055/s-0043-118749
Article
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Aldosterone on Chemerin Expression And Secretion in 3T3-L1 Adipocytes

Junhua Ma   *
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Fei Sun   *
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Jingnan Wang   *
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
He Jiang
2   Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
,
Jiancan Lu
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Xing Wang
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Jichen Zhang
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Chao Shi
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Wen You
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Xiangqi Li
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Hongling Zhu
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
,
Mingjun Gu
1   Department of Endocrinology, Shanghai Gongli Hospital, the Second Military Medical University, Shanghai 200135, China
› Author Affiliations
Further Information

Publication History

received 11 June 2017
revised 03 August 2017

accepted 22 August 2017

Publication Date:
20 September 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Aldosterone plays a pivotal role in the pathogenesis of metabolic syndrome and cardiovascular disease; however, the underlying mechanisms have not been clarified. Chemerin has been characterized as an adipokine with crucial roles in obesity-associated disorders and cardiovascular homeostasis. The aim of the present study was to investigate the direct effects of aldosterone on chemerin expression and secretion in 3T3-L1 adipocytes and to identify the potential signalling pathways involved. Chemerin mRNA levels were measured using real-time PCR, whereas the levels of secreted chemerin in the culture media were determined using ELISA. Treatment with aldosterone induced time- and dose-dependent increases of chemerin gene expression and protein secretion, and effect that was mediated through the mineralocorticoid receptor. Signalling studies suggested that the NF-κB pathway is involved in aldosterone-induced chemerin expression. Taken together, our data demonstrate a direct interaction between aldosterone and chemerin in adipocytes, which may be an underlying mechanism linking aldosterone-associated metabolic abnormalities and cardiovascular disease.

Key words

aldosterone - chemerin - 3T3-L1 adipocyte - metabolic syndrome - cardiovascular disease

* These authors contributed equally to this work.


 

  • References

  • 1 Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697
    CrossrefPubMedGoogle Scholar
  • 2 Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?. Hypertension 2008; 51: 1252-1258
    CrossrefPubMedGoogle Scholar
  • 3 Catena C, Lapenna R, Baroselli S. et al. Insulin sensitivity in patients with primary aldosteronism: A follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463
    CrossrefPubMedGoogle Scholar
  • 4 Catena C, Colussi G, Nadalini E. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
    CrossrefPubMedGoogle Scholar
  • 5 Born-Frontsberg E, Reincke M, Rump LC. et al. Participants of the German Conn’s Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
    CrossrefPubMedGoogle Scholar
  • 6 Fallo F, Veglio F, Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
    CrossrefPubMedGoogle Scholar
  • 7 Fallo F, Federspil G, Veglio F. et al. The metabolic syndrome in primary aldosteronism. Curr Diab Rep 2008; 8: 42-47
    CrossrefPubMedGoogle Scholar
  • 8 Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17: 332-341
    CrossrefPubMedGoogle Scholar
  • 9 Ehrhart-Bornstein M, Arakelyan K, Krug AW. et al. Fat cells may be the obesity-hypertension link: Human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004; 30: 865-870
    CrossrefPubMedGoogle Scholar
  • 10 Fallo F, Della Mea P, Sonino N. et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007; 20: 855-861
    CrossrefPubMedGoogle Scholar
  • 11 Iacobellis G, Petramala L, Cotesta D. et al. Adipokines and Cardiometabolic Profile in Primary Hyperaldosteronism. J Clin Endocrinol Metab 2010; 95: 2391-2398
    CrossrefPubMedGoogle Scholar
  • 12 Irita J, Okura T, Manabe S. et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006; 19: 293-297
    CrossrefPubMedGoogle Scholar
  • 13 Staermose S, Marwick TH, Gordon RD. et al. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension 2009; 53: e31-e32
    CrossrefPubMedGoogle Scholar
  • 14 Carvajal CA, Herrada AA, Castillo CR. et al. Primary aldosteronism can alter peripheral levels of transforming growth factor β and tumor necrosis factor α. J Endocrinol Invest 2009; 32: 759-765
    CrossrefPubMedGoogle Scholar
  • 15 Li P, Zhang XN, Pan CM. et al. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 2011; 43: 464-469
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Jiang H, Ye XP, Yang ZY. et al. Aldosterone directly affects apelin expression and secretion in adipocytes. J Mol Endocrinol 2013; 51: 37-48
    CrossrefPubMedGoogle Scholar
  • 17 Guo C, Ricchiuti V, Lian BQ. et al. Mineralocorticoid receptor blockade reverses obesityrelated changes in expression of adiponectin, peroxisome proliferatoractivated receptor-γ, and proinflammatory adipokines. Circulation 2008; 117: 2253 -2261
    CrossrefPubMedGoogle Scholar
  • 18 Goralski KB, McCarthy TC, Hanniman EA. et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282: 28175-28188
    CrossrefPubMedGoogle Scholar
  • 19 Jialal I, Devaraj S, Kaur H. et al. Increased Chemerin and Decreased Omentin-1 in Both Adipose Tissue and Plasma in Nascent Metabolic Syndrome. J Clin Endocrinol Metab 2013; 98: E514-E517
    CrossrefPubMedGoogle Scholar
  • 20 Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011; 22: 331-338
    CrossrefPubMedGoogle Scholar
  • 21 Yan Q, Zhang Y, Hong J. et al. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 2011; 41: 281-288
    PubMedGoogle Scholar
  • 22 Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med 2011; 50: 1093-1097
    CrossrefPubMedGoogle Scholar
  • 23 İnci S, Aksan G, Doğan P. Chemerin as an independent predictor of cardiovascular event risk. Ther Adv Endocrinol Metab 2016; 7: 57-68
    CrossrefPubMedGoogle Scholar
  • 24 Yu QX, Zhang H, Xu WH. et al. Effect of irbesartan on chemerin in the renal tissues of diabetic rats. Kidney Blood Press Res 2015; 40: 467-477
    CrossrefPubMedGoogle Scholar
  • 25 Huang H, Hu L, Lin J. et al. Effect of fosinopril on chemerin and VEGF ex- pression in diabetic nephropathy rats. Int J Clin Exp Pathol 2015; 8: 11470-11474
    PubMedGoogle Scholar
  • 26 Li RY, Song HD, Shi WJ. et al. Galanin inhibits leptin expression and secretion in rat adipose tissue and 3T3-L1 adipocytes. J Mol Endocrinol 2004; 33: 11-19
    CrossrefPubMedGoogle Scholar
  • 27 Ma QY, Zhang XN, Jiang H. et al. Mimecan in pituitary corticotroph cells may regulate ACTH secretion and the HPAA. Molecular and Cellular Endocrinology 2011; 341: 71-77
    CrossrefPubMedGoogle Scholar
  • 28 Boldyreff B, Wehling M. Rapid aldosterone actions: From the membrane to signaling cascades to gene transcription and physiological effects. J Steroid Biochem Mol Biol 2003; 85: 375-381
    CrossrefPubMedGoogle Scholar
  • 29 Feraco A, Armani A, Mammi C. et al. Role of mineralocorticoid receptor and reninangiotensin-aldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol 2013; 137: 99-106
    CrossrefPubMedGoogle Scholar
  • 30 Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A. et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003; 100: 14211-14216
    CrossrefPubMedGoogle Scholar
  • 31 Kraus D, Jäger J, Meier B. et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005; 37: 455-459
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Hoppmann J, Perwitz N, Meier B. et al. The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 2010; 204: 153-164
    CrossrefPubMedGoogle Scholar
  • 33 Pitt B, Remme W, Zannad F. et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
    CrossrefPubMedGoogle Scholar
  • 34 Urbanet R, Nguyen Dinh Cat A, Feraco A. et al. Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin d2 synthase. Hypertension 2015; 66: 149-157
    CrossrefPubMedGoogle Scholar
  • 35 Hirata A, Maeda N, Hiuge A. et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-172
    CrossrefPubMedGoogle Scholar
  • 36 Mattern A, Zellmann T, Beck-Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life 2014; 66: 19-26
    CrossrefPubMedGoogle Scholar
  • 37 Parlee SD, Ernst MC, Muruganandan S. et al. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology 2010; 151: 2590-2602
    CrossrefPubMedGoogle Scholar
  • 38 Kralisch S, Weise S, Sommer G. et al. Interleukin-1ß induces the novel adipokine chemerin in adipocytes in vitro. Regulatory Peptides 2009; 154: 102-106
    CrossrefPubMedGoogle Scholar
  • 39 Senftleben U, Karin M. The IKK/NF-κB pathway. Crit Care Med 2002; 30: 18-26
    PubMedGoogle Scholar
  • 40 de Winther MP, Kanters E, Kraal G. et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 25: 904-914
    CrossrefPubMedGoogle Scholar